Background:
- The anticancer drug bevacizumab works by reducing the formation of new blood vessels in tumors, which can slow or stop the growth of cancer cells and supporting blood vessels. The experimental drug EZN-2208 works by limiting how well cancer cells can divide. Drugs similar to EZN-2208 also work by turning off the production of the HIF protein, which otherwise can help cancer cells to grow even when blood supply is limited. Researchers are interested in determining if EZN-2208 turns off HIF in patient tumors, and whether combining it with bevacizumab is an effective treatment for cancers that have not responded to standard treatment.
Objectives:
- To assess the safety and effectiveness of the combination of EZN-2208 and bevacizumab for solid tumors that have not responded to standard treatment.
Eligibility:
- Individuals at least 18 years of age who have solid tumors that have not responded to standard treatment.
Design:
Participants will be screened with a full physical examination and medical history, blood and urine samples, and tumor imaging studies.
Participants will receive EZN-2208 and bevacizumab intravenously on an outpatient basis in 4-week cycles (with the exception of the first cycle, which will be 5 weeks).
Cycle 1: Participants will receive EZN-2208 once a week for 3 weeks in a row (days 1, 8, and 15), followed by 1 week without the drug. Participants will receive bevacizumab 1 week before EZN-2208 (day - 7) and then 3 weeks later (day 15).
Subsequent cycles: Participants will receive EZN-2208 once a week for 3 weeks in a row (days 1, 8, and 15), followed by 1 week without the drug. Participants will receive bevacizumab every 2 weeks (days 1 and 15).
Participants will have clinic visits with physical examinations and blood tests in the first 3 weeks of each cycle. Clinic visits may also include tumor imaging studies and tumor biopsies as directed by the study researchers.
Participants will continue to take the study drugs for as long as the tumor shrinks or does not grow, and as long as they do not experience intolerable or unsafe side effects from the drugs.

开始日期2010-11-15

申办/合作机构

National Cancer Institute

NCT01295697 / Terminated临床1/2期

A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety of the study drug and its effect on the disease will also be studied.

开始日期2010-02-01

申办/合作机构

Enzon Pharmaceuticals, Inc.

NCT01036113 / Terminated临床2期

A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)

This is a Phase 2, multicenter, open-label, noncomparative study to evaluate safety,efficacy and of single-agent EZN 2208 administered in patients with previously treated MBC.
After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.

开始日期2009-11-01

申办/合作机构

Enzon Pharmaceuticals, Inc.

100 项与 Firtecan pegol 相关的临床结果

登录后查看更多信息

100 项与 Firtecan pegol 相关的转化医学

登录后查看更多信息

100 项与 Firtecan pegol 相关的专利（医药）

登录后查看更多信息

项与 Firtecan pegol 相关的文献（医药）

2020-05-01·Open biology2区 · 生物学

EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine

2区 · 生物学

ArticleOA

作者: Bongiovanni, Lucia ; Bernardi, Rosa ; Valsecchi, Roberta ; Scarfò, Lydia ; Ghia, Paolo ; Magliulo, Daniela ; Ponzoni, Maurilio ; Coltella, Nadia

The transcription factor HIF-1α is overexpressed in chronic lymphocytic leukaemia (CLL), where it promotes leukaemia progression by favouring the interaction of leukaemic cells with protective tissue microenvironments. Here, we tested the hypothesis that a pharmacological compound previously shown to inhibit HIF-1α may act as a chemosensitizer by interrupting protective microenvironmental interactions and exposing CLL cells to fludarabine-induced cytotoxicity. We found that the camptothecin-11 analogue EZN-2208 sensitizes CLL cells to fludarabine-induced apoptosis in cytoprotective in vitro cultures; in vivo EZN-2208 improves fludarabine responses, especially in early phases of leukaemia expansion, and exerts significant anti-leukaemia activity, thus suggesting that this or similar compounds may be considered as effective CLL therapeutic approaches.

2015-08-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα–Driven Leukemia

1区 · 医学

Article

作者: Ponente, Manfredi ; Valsecchi, Roberta ; Bernardi, Rosa ; Ponzoni, Maurilio ; Coltella, Nadia

Abstract:

Purpose: Retinoic acid-arsenic trioxide (ATRA-ATO) combination therapy is the current standard of care for patients with acute promyelocytic leukemia (APL) carrying the oncogenic fusion protein PML-RARα. Despite the high cure rates obtained with this drug combination, resistance to arsenic is recently emerging. Moreover, patients with APL carrying the PLZF-RARα fusion protein are partially resistant to ATRA treatment. Hypoxia-inducible factor-1α (HIF-1α) activation has been recently reported in APL, and EZN-2208 (PEG-SN38) is a compound with HIF-1α inhibitory function currently tested in clinical trials. This study investigates the effect of EZN-2208 in different preclinical APL models, either alone or in combination with ATRA.Experimental Design: Efficacy of EZN-2208 in APL was measured in vitro by assessing expression of HIF-1α target genes, cell migration, clonogenicity, and differentiation, vis a vis the cytotoxic and cytostatic effects of this compound. In vivo, EZN-2208 was used in mouse models of APL driven by PML-RARα or PLZF-RARα, either alone or in combination with ATRA.Results: Treatment of APL cell lines with noncytotoxic doses of EZN-2208 causes dose-dependent downregulation of HIF-1α bona fide target genes and affects cell migration and clonogenicity in methylcellulose. In vivo, EZN-2208 impairs leukemia progression and prolongs mice survival in APL mouse models. More importantly, when used in combination with ATRA, EZN-2208 synergizes in debulking leukemia and eradicating leukemia-initiating cells.Conclusions: Our preclinical data suggest that the combination ATRA-EZN-2208 may be tested to treat patients with APL who develop resistance to ATO or patients carrying the PLZF-RARα fusion protein. Clin Cancer Res; 21(16); 3685–94. ©2015 AACR.

2014-10-01·Pediatric blood & cancer3区 · 医学

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors

3区 · 医学

Article

作者: Macy, Margaret E. ; Fox, Elizabeth ; Berkowitz, Noah ; Buchbinder, Aby ; Muscal, Jodi A. ; Gore, Lia ; Bagatell, Rochelle ; Shusterman, Suzanne ; Norris, Robin E.

BACKGROUND:

EZN-2208 is a water-soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of irinotecan. Compared to irinotecan, EZN-2208 has a prolonged half-life permitting extended exposure to SN38. EZN-2208 has demonstrated clinical tolerability and antitumor activity in adults with advanced solid tumors. This Phase 1 study evaluated the safety, pharmacokinetics, and preliminary antitumor activity of EZN-2208 in children with relapsed or refractory solid tumors.

PROCEDURE:

EZN-2208 was administered as a 1-hour intravenous infusion once every 21 days at five dose levels (12-30 mg/m(2) ). Filgrastim or pegfilgrastim was administered 24-48 hours after treatment with EZN-2208. The rolling-six design was used for dose determination.

RESULTS:

Thirty eligible patients (15 females; median [range] age 11.5 years [2-21 years]) were treated with EZN-2208. Dose-limiting diarrhea occurred in one patient receiving 16 mg/m(2) and dose-limiting dehydration was seen in one patient receiving 24 mg/m(2) . At dose levels above 16 mg/m(2) , Grade ≥3 myelosuppression was demonstrated in the majority of patients. Additional adverse events included nausea, vomiting, and fatigue. The maximum tolerated dose was identified as 24 mg/m(2) due to dose-limiting thrombocytopenia in two patients receiving 30 mg/m(2) . Two of nine patients with neuroblastoma who were evaluable for response had partial responses. Five patients (four with neuroblastoma) remained on study for ≥8 cycles.

CONCLUSIONS:

EZN-2208 was generally well-tolerated and was associated with clinical benefit in patients with neuroblastoma.

项与 Firtecan pegol 相关的新闻（医药）

2023-01-26

·PRNewswire

SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

First Generic of Abraxane in Korea, World 4th Commercial Scale-Up Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea, Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEO Jang Doo-hyun) signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anticancer drug (code name: SNA-001) developed by SN BioScience for the first time in Korea and the fourth time in the world. Through this contract, Boryeong will have exclusive manufacturing and distribution rights in Korea for "SNA-001." SN BioScience will receive milestones and double-digit royalties according to the development stage. SN BioScience also signed a domestic distribution agreement with Boryeong in February 2021 for SNB-101, a polymer nanoparticle new drug, and expects a variety of cooperations in the field of anticancer drugs in the future. "SNA-001" is a product that electrostatically binds cytotoxic anticancer drugs to albumin using albumin present in human blood as a drug carrier. Abraxane is a global blockbuster first developed by Abraxis BioScience Inc (acquired by Celgene who became a subsidiary of BMS), with sales of $1.5 billion worldwide in 2020. Albumin has been studied as a carrier that delivers various drugs into cells through electrostatic or chemical bonds with excellent biocompatibility as about 66,000 Dalton of drug transport protein in the blood. Despite the advantages, there has been challenges in commercial scale-up. Even BMS, the original manufacturer, has gone through global shortages from 2019 to 2021 due to manufacturing/quality issues. Only a few companies around the world, such as Teva, have succeeded in scale-up production to date. Based on the commercial scale-up technology for nanoparticle drugs accumulated through SNB-101 (API: SN-38, firtecan), a nanoparticle anticancer drug that has already entered phase 1, SN BioScience has completed the development of a commercial-scale manufacture process for the Abraxane's generic for the fourth time in the world. SN BioScience developed a superior manufacturing process with a yield of more than 90% and a particle size deviation of less than 7%, which is evaluated as having excellent quality and reproducibility compared to products of competitors with a yield of about 70 to 80%. SNA-001 showed excellent efficacy in solid cancer animal models in non-clinical studies. In the characterization of the in vivo behavior of nanoparticles, it was suitable for key evaluation indicators such as free and encapsulated drug concentrations and drug accumulation in major organs. Based on the above, SN BioScience is discussing the technology transfer with global leading pharmaceutical companies in the United States, Japan, and Europe, while on the other hand, it is discovering new indications by applying albumin-based nanoparticle platforms to various anticancer drugs. The company is also planning to file phase 1 IND for two to three new nanoparticle anticancer drugs in the second half of this year. About SN BioScience Inc SN BioScience is a biotech company established in May 2017, a drug delivery system R&D company specialized in anti-cancer drugs, and is located in the 2nd Pangyo Techno Valley in Seongnam-si, Gyeonggi-do, Korea. SN BioScience was founded by pharmaceutical R&D experts, world-class bio-polymer research professors, and clinical professors. From the beginning of its establishment, it has been developing nanoliposomes and nanoparticle drug carriers based on drug metrology and pharmacokinetics. The main pipelines include polymeric nanoparticle anticancer drugs (on-going phase I in Korea) and albumin nanoparticle anticancer drugs (phase I IND filed). About Boryung Co., Ltd Founded in 1957, Boryeong Co., Ltd. is a top-tier pharmaceutical company in Korea that manufactures and sells drugs for chronic diseases such as hypertension, diabetes, brain disease, and anticancer, with sales of about USD 550 million in 2022. In addition, the company has produced various and successful research results, including Kanarb Tab., a new drug for high blood pressure, and has the highest market share in Korea, especially in the field of anticancer drugs. SOURCE SN BioScience Inc

临床1期引进/卖出并购上市批准

100 项与 Firtecan pegol 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10464	-	-	DB14953

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性实体肿瘤	临床2期	美国	Enzon Pharmaceuticals, Inc.	2010-02-01
转移性乳腺癌	临床2期	美国	Enzon Pharmaceuticals, Inc.	2009-11-01
转移性结直肠癌	临床2期	美国	Enzon Pharmaceuticals, Inc.	2009-06-01
转移性结直肠癌	临床2期	加拿大	Enzon Pharmaceuticals, Inc.	2009-06-01
转移性结直肠癌	临床2期	以色列	Enzon Pharmaceuticals, Inc.	2009-06-01
转移性结直肠癌	临床2期	荷兰	Enzon Pharmaceuticals, Inc.	2009-06-01
转移性结直肠癌	临床2期	英国	Enzon Pharmaceuticals, Inc.	2009-06-01
晚期恶性实体瘤	临床1期	美国	Enzon Pharmaceuticals, Inc.	2007-05-01
淋巴瘤	临床1期	美国	Enzon Pharmaceuticals, Inc.	2007-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2012	临床2期	转移性乳腺癌辅助	164	EZN-2208 9 mg/m2	憲餘顧醖鹹窪壓觸窪窪(獵蓋窪選築糧糧網糧鑰) = 獵鹹積積衊願襯製蓋鹹壓襯廠鹽廠糧鑰憲簾簾 (夢夢夢蓋餘艱淵艱選簾 ) 更多	-	2012-05-20